L-glutamyl-L-valine | 5879-06-1

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-glutamyl-L-valine
• 英文别名: glutamylvaline；H-Glu-Val-OH；Glu-Val；α-Glu-Val；EV；N-L-α-glutamyl-L-valine；L-Glu-L-Val；(2S)-2-[[(2S)-2-azaniumyl-4-carboxybutanoyl]amino]-3-methylbutanoate
• CAS: 5879-06-1
• 化学式: C₁₀H₁₈N₂O₅
• 分子量: 246.263
• InChiKey: SITLTJHOQZFJGG-XPUUQOCRSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  lead 、 L-glutamyl-L-valine 生成
  参考文献：
  名称：

  Effect of the types and arrangements of donor atoms on Pb(II) versus Zn(II) binding preference of selected amino acids, peptides and derivatives

  摘要：

  Pb(II) complexes in solution formed with different amino acids [glycine (Gly), aspartic acid (Asp), histidine (His), methionine (Met), S-methyl-cysteine (SMC) and penicillamine (Pen)], dipeptides (GlyGly, GlyVal (Val = valine), GlyMet, MetGly, GlyHis, HisGly, GlyAsp, AspGly, CysGly (Cys = cysteine), AlaCys, GlyGlu (Glu = glutamic acid), GluVal, SerGly (Ser = serine)), tripeptides (GlyGlyGly, GlyMetGly, GlyGlyMet, MetMetMet), as well as two peptidehydroxamic acids [(alanyl-alanine hydroxamic acid (AlaAlaNHOH) and N-methyl-alanyl-alanine hydroxamic acid AlaAlaN(CH3)OH)] have been studied by pH-potentiometry, H-1 NMR and ESI-MS measurements. The effects of the types and arrangements of the donor atoms on the Pb(II)-binding ability as well as on the selectivity for Pb(II) over Zn(II) were evaluated. Out of the investigated molecules, the Pb(II) binding ability of Pen is far the best, but compared to this ligand, somewhat better selectivity for Pb(II) over Zn(II) can be achieved with S-containing dipeptides. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2014.07.074
• 作为产物：
  描述：

  L-缬氨酸甲酯盐酸盐 在 palladium on activated charcoal manganese(IV) oxide 、 sodium hydroxide 、 氢气 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 25.0 ℃ 、202.65 kPa 条件下， 生成 L-glutamyl-L-valine
  参考文献：
  名称：

  Phenylhydrazide as a Protective Group in Peptide Synthesis. The Oxidation of γ-Phenylhydrazides of N-Carbobenzoxy-α-L-glutamylamino Acid Esters with Manganese Dioxide

  摘要：

  DOI：

  10.1021/jo01037a043

文献信息

• USE OF PEPTIDES FOR IMPARTING KOKUMI
  申请人：FUTAKI FUMIE

  公开号：US20120034364A1

  公开（公告）日：2012-02-09

  The inventors of this invention have conducted the search for a variety of compounds which may possess a desired CaSR agonist activity to thus find out a substance capable of imparting a kokumi, which shows a more excellent kokumi-imparting effect, in particular, a kokumi-imparting effect of the initial taste-imparting type one, which is excellent in the stability and which can easily be produced at a low cost and the present invention thus provide a kokumi-imparting agent consisting of such a substance as well as a complex kokumi-imparting agent comprising the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting agent consisting of γ-Glu-Abu (L-γ-glutamyl-L-2-amino-butyric acid) and a complex kokumi-imparting agent comprising the foregoing substance and another substance having a CaSR agonist activity, in combination.

  本发明的发明者们已经寻找了多种可能具有所需CaSR激动剂活性的化合物，以此找到一种能够赋予kokumi的物质，该物质具有更出色的kokumi赋予效果，特别是初始味道赋予型的kokumi赋予效果，稳定性优异，成本低廉且易于生产。因此，本发明提供了由这种物质组成的kokumi赋予剂，以及由该物质和其他具有CaSR激动剂活性的物质组合而成的复合kokumi赋予剂。更具体地说，本发明提供了由γ-Glu-Abu（L-γ-谷氨酰-L-2-氨基丁酸）组成的kokumi赋予剂，以及由上述物质和另一种具有CaSR激动剂活性的物质组合而成的复合kokumi赋予剂。
• DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1941896A1

  公开（公告）日：2008-07-09

  The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula:         X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.

  本发明提供了一种口服组合物，它包含至少一种由式表示的二肽： X-Y (其中 X 代表丙氨酰、甘氨酰、精氨酰、丝氨酰、α-天冬氨酰或α-谷氨酰，Y 代表缬氨酸、亮氨酸或异亮氨酸），其目的是提供一种营养、药效和口感俱佳的口服组合物，该组合物至少包含一种选自缬氨酸、亮氨酸和异亮氨酸的二肽、或提供一种口服组合物，该组合物在加工特性（如溶解性和压片性能）方面非常出色，并包含至少一种选自缬氨酸、亮氨酸和异亮氨酸的成分。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。
• Method of assessing pancreatic beta-cell function
  申请人：Gall Walter

  公开号：US10302663B2

  公开（公告）日：2019-05-28

  Biomarkers relating to pancreatic Beta-cell function, pancreatic Beta-cell glucose sensitivity, insulin resistance, and/or pancreatic Beta-cell-related disorders are provided. Methods based on the same biomarkers are also provided.

  提供了与胰岛β细胞功能、胰岛β细胞葡萄糖敏感性、胰岛素抵抗和/或胰岛β细胞相关疾病有关的生物标志物。还提供了基于相同生物标志物的方法。
• Gastrointestinal tract detection methods, devices and systems
  申请人：Progenity Inc.

  公开号：US10610104B2

  公开（公告）日：2020-04-07

  The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

  本公开涉及胃肠道（GI）检测方法、装置和系统。